(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture...
Stats | |
---|---|
今日成交量 | 12 466.00 |
平均成交量 | 11 339.00 |
市值 | 0.00 |
EPS | $0.0271 ( 2022-01-30 ) |
Last Dividend | $0.656 ( 2021-03-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6 265.00 |
ATR14 | $0 (0.00%) |
Avid Bioservices, Inc. 财务报表
Annual | 2023 |
营收: | $149.27M |
毛利润: | $31.48M (21.09 %) |
EPS: | $0.00900 |
FY | 2023 |
营收: | $149.27M |
毛利润: | $31.48M (21.09 %) |
EPS: | $0.00900 |
FY | 2022 |
营收: | $119.60M |
毛利润: | $36.65M (30.64 %) |
EPS: | $2.08 |
FY | 2021 |
营收: | $95.87M |
毛利润: | $29.31M (30.57 %) |
EPS: | $0.198 |
Financial Reports:
No articles found.
Avid Bioservices, Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.299 | 2014-03-19 |
Last Dividend | $0.656 | 2021-03-12 |
Next Dividend | $0 | N/A |
Payout Date | 2021-04-01 | |
Next Payout Date | N/A | |
# dividends | 29 | -- |
Total Paid Out | $18.67 | -- |
Avg. Dividend % Per Year | 1.06% | -- |
Score | 2.21 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0.0723 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $2.62 | 14.70% |
2019 | $2.62 | 12.90% |
2020 | $2.62 | 11.10% |
2021 | $0.656 | 2.40% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.131 | 1.500 | -2.62 | -3.93 | [0 - 0.5] |
returnOnAssetsTTM | -0.0394 | 1.200 | -1.312 | -1.574 | [0 - 0.3] |
returnOnEquityTTM | -0.0963 | 1.500 | -2.18 | -3.27 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.465 | 0.800 | -2.68 | -2.14 | [1 - 3] |
quickRatioTTM | 0.297 | 0.800 | -2.96 | -2.37 | [0.8 - 2.5] |
cashRatioTTM | 0.138 | 1.500 | -0.346 | -0.519 | [0.2 - 2] |
debtRatioTTM | 0.431 | -1.500 | 2.81 | -4.22 | [0 - 0.6] |
interestCoverageTTM | -10.85 | 1.000 | -5.13 | -5.13 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.194 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.608 | 2.00 | -0.304 | -0.608 | [0 - 20] |
debtEquityRatioTTM | 1.090 | -1.500 | 5.64 | -8.46 | [0 - 2.5] |
grossProfitMarginTTM | 0.0747 | 1.000 | -2.09 | -2.09 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.132 | 1.000 | -4.64 | -4.64 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0627 | 1.000 | -0.763 | -0.763 | [0.2 - 2] |
assetTurnoverTTM | 0.300 | 0.800 | -1.331 | -1.065 | [0.5 - 2] |
Total Score | -0.942 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -25.98 | 1.000 | -2.72 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0963 | 2.50 | -1.402 | -3.27 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.608 | 2.00 | -0.203 | -0.608 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.194 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.261 | 1.500 | -1.594 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0900 | 1.000 | -0.250 | 0 | [0.1 - 0.5] |
Total Score | 0.0723 |
Avid Bioservices, Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。